Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederpubmed.ncbi.nlm.nih.gov
Durva OR Treme OR Pembrolizumab OR nivolumab OR atezolizumab OR sasanlimab OR tarlatamab AND lung cancer AND 2025:2025[pdat] AND 2025:2025[pdat]
Get the latest updates from Durva OR Treme OR Pembrolizumab OR nivolumab OR atezolizumab OR sasanlimab OR tarlatamab AND lung cancer AND 2025:2025[pdat] AND 2025:2025[pdat] directly as they happen.
Follow now 169 followers
Latest posts
Last updated about 2 hours ago
Stratification by PD-L1 TPS in Advanced NSCLC With Low PD-L1 Expression for Optimizing Immunotherapy
about 21 hours ago
Anticancer Res. 2025 Sep;45(9):3859-3875. doi: 10.21873/anticanres.17745.ABSTRACTBACKGROUND: The optimal treatment for advanced non-small-cell...
The Multifaceted Role of Growth Differentiation Factor 15 (GDF15): A Narrative Review from Cancer Cachexia to Target Therapy
about 21 hours ago
Biomedicines. 2025 Aug 8;13(8):1931. doi: 10.3390/biomedicines13081931.ABSTRACTBackground: Growth Differentiation Factor 15 (GDF15) has...
Real-World Effectiveness and Safety of Immune Checkpoint Inhibitors Combined with Chemotherapy in Taiwanese Patients with Extensive-Stage Small Cell Lung Cancer
2 days ago
Curr Oncol. 2025 Aug 19;32(8):472. doi: 10.3390/curroncol32080472.ABSTRACTPURPOSE: Extensive-stage small cell lung cancer...
Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 for the treatment of extracranial oligometastatic non-small cell lung cancer with radiosurgery
2 days ago
Pract Radiat Oncol. 2025 Aug 25:S1879-8500(25)00215-2. doi: 10.1016/j.prro.2025.07.008. Online ahead of print.ABSTRACTBACKGROUND...
Comment on "The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non-Small-Cell lung cancer"
2 days ago
Lung Cancer. 2025 Aug 24;207:108725. doi: 10.1016/j.lungcan.2025.108725. Online ahead of print.NO ABSTRACTPMID:40865374...
CREPT promotes LUAD progression by enhancing the CDK9 and RNAPII assembly to promote ERK-driven gene transcription
2 days ago
Theranostics. 2025 Jul 25;15(16):8337-8359. doi: 10.7150/thno.115572. eCollection 2025.ABSTRACTBackground: Despite advancements in EGFR-...
Pleomorphic carcinoma of the lung with paraneoplastic fever as presentation
2 days ago
Indian J Thorac Cardiovasc Surg. 2025 Sep;41(9):1207-1211. doi: 10.1007/s12055-025-01976-x. Epub 2025 May...
MiRNA-Based Exosome-Targeted Multi-Target, A Multi-Pathway Intervention for Personalized Lung Cancer Therapy: Prognostic Prediction and Survival Risk Assessment
2 days ago
Iran J Biotechnol. 2025 Apr 1;23(2):e4112. doi: 10.30498/ijb.2025.516588.4112. eCollection 2025 Apr.ABSTRACTBACKGROUND: Lung...
Predictors of outcomes in advanced non-small cell lung cancer treated with pembrolizumab maintenance
4 days ago
Oncologist. 2025 Aug 4;30(8):oyaf070. doi: 10.1093/oncolo/oyaf070.ABSTRACTBACKGROUND: Real-world first-line maintenance (1LM) treatment data...
Long-term survival after resolution of pulmonary metastasis in a patient with unresectable cervical esophageal carcinoma after nivolumab-induced immune-related adverse events
6 days ago
Clin J Gastroenterol. 2025 Aug 24. doi: 10.1007/s12328-025-02207-x. Online ahead of print.ABSTRACTNivolumab...
VEGF Signal Complexity Confers Resistance to Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
7 days ago
MedComm (2020). 2025 Aug 19;6(9):e70335. doi: 10.1002/mco2.70335. eCollection 2025 Sep.ABSTRACTAtezolizumab, bevacizumab, carboplatin...
Combining Immune Checkpoint Inhibitors and Anti-Angiogenesis Approaches: Treatment of Advanced Non-Small Cell Lung Cancer
7 days ago
Med Sci (Basel). 2025 Aug 19;13(3):143. doi: 10.3390/medsci13030143.ABSTRACTCombining immune checkpoint inhibitors (ICIs)...